ClinicalTrials.gg
RecruitingNCT04991922Updated Oct 7, 2026

BostonGene-Integrated Genomic Registry (BIGR)

An observational study in Malignancy, sponsored by BostonGene. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by BostonGene · Observational

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.
Updated Oct 7, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100,000
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types

Read the detailed description

Immuno- and targeted therapies have shown promising results for many types of cancer (1). However, the effectiveness of these treatments is not optimal for many patients (2). Therefore, further research is needed to discover, define, and develop genomic, transcriptomic, and integrated molecular markers that can improve clinical outcomes across cancer types (3). Unfortunately, current research is restricted by the limited availability of genomic and transcriptomic results linked to clinical outcomes (3). This study will allow for the collection of key clinical data, including longitudinal follow-up, linked with individual genetic and molecular findings in a single comprehensive registry-based databank. Analysis of these data may lead to advances across cancer subtypes through the identification of transcriptomic and genomic associations with therapies.

Clinical and pathological information, including detailed genetic information from a participant's tumor biopsy, will be obtained by the research staff for each participant enrolled in the BIGR Study. Clinical information will include relevant details about the patient's diagnosis and treatment and will be stored in a secure electronic registry database. No extra scans or procedures for this study will be collected as part of this study. Information will be collected regarding a participant's initial diagnosis, treatment, and outcome. To obtain this information, study staff will contact participants or a participant's doctor at regular time intervals for up to 15 years.

02

Conditions studied

  • Malignancy

Browse trials for

Keywords

  • cancer
  • precision medicine
  • WES
  • RNA-seq
  • immuno-therapy
  • genomic
  • transcriptomic
  • multiomic
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 100,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

BostonGene is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will be identified for the BIGR study from a larger group of patients undergoing BostonGene clinical testing (e.g., BostonGene Tumor Portrait TestTM).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Suspected or confirmed
  2. Planned comprehensive genomic (> 100 genes) and/or molecular analysis; or genomic and/or molecular data available from prior sequencing
  3. Baseline demographics and treatment information available
  4. Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment.
  5. Signed to participate in the study.
  6. Living in the United States at the time of enrollment

Exclusion criteria

Exclusion Criteria:

\< 3 months

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. association between major finding and outcome, Descriptive

    associations between genomic findings and outcomes of cancer patients who have undergone comprehensive sequencing.

    Time frame: 5 years

Secondary outcomes

  1. Predictive probability

    identify molecular findings associated with therapy.

    Time frame: 5 years

  2. Clinical trials matching

    identify and link registry subjects to future molecular-based clinical research

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • BostonGene
    Waltham, Massachusetts 02453, United States
    Recruiting
08

References and documents

Publications

  • Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020 Jun;30(6):507-519. doi: 10.1038/s41422-020-0337-2. Epub 2020 May 28. PubMed 32467593 ↗
  • Sambi M, Bagheri L, Szewczuk MR. Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates. J Oncol. 2019 Feb 28;2019:4508794. doi: 10.1155/2019/4508794. eCollection 2019. PubMed 30941175 ↗
  • Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. The Need for Multi-Omics Biomarker Signatures in Precision Medicine. Int J Mol Sci. 2019 Sep 26;20(19):4781. doi: 10.3390/ijms20194781. PubMed 31561483 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Jul 2031, 120 months after the start.

Of 148 industry-sponsored observational studies under Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 102. This study's planned 120 months is above that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2021
First posted
Aug 5, 2021
StartActual
Jul 1, 2021
Primary completionEst.
Jul 1, 2031
CompletionEst.
Jul 1, 2036
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: n•••@bostongene.com · •••4545→n•••@bostongene.com · •••3131. See the current contact
Oct 7, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • BostonGene · Waltham, United StatesContact k•••@bostongene.com · •••4545→n•••@bostongene.com · •••3131
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Contact Study contact changed: n•••@bostongene.com · •••4545→n•••@bostongene.com · •••3131. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • BostonGene · Waltham, United StatesContact k•••@bostongene.com · •••4545→n•••@bostongene.com · •••3131
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04991922
Lead sponsor
BostonGene
Responsible party
Sponsor
First posted
Aug 5, 2021
Start date
Jul 1, 2021
Primary completion
Jul 1, 2031 (estimated)
Completion
Jul 1, 2036 (estimated)
Last update
Oct 7, 2026

Study contacts

Nathan Fowler, MD
Contact
nathan.fowler@bostongene.com
+17815523131
Nathan Fowler
principal investigator · BostonGene

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion